Home » EntreMed Begins Pancreatic Cancer Study
EntreMed Begins Pancreatic Cancer Study
EntreMed has started a Phase II trial with MKC-1 in patients with advanced pancreatic cancer.
The multicenter study will determine the antitumor activity of orally administered MKC-1 in patients who have failed at least one chemotherapy regimen.
The study also will assess the safety, tolerability and overall median survival time of patients treated with the drug, EntreMed said.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May